脑结构在患有无记忆症轻度认知障碍的患者和患有阿尔茨海默病的患者之间存在差异
Xiaorui Cui1, Mingpeng Li2, Guanxiong Lei3,4
1Department of Neurology, Affiliated Hospital of Xiangnan University, Chenzhou, China.
Frontiers in aging neuroscience
|December 19, 2024
概括
在前和下部区域的结构性大脑差异与阿尔茨海默病 (AD) 和轻度认知障碍 (MCI) 有关. 这些发现可能有助于识别早期AD诊断的潜在生物标志物.
科学领域:
- 神经成像是一种神经成像.
- 神经学 神经学
- 放射学 放射学是指放射学
背景情况:
- 阿尔茨海默氏症 (AD) 的特点是脑缩的进展.
- 了解阿尔茨海默病进展期间的大脑结构变化至关重要.
- 这项研究调查了记忆力轻度认知障碍 (aMCI) 和AD患者的大脑结构差异.
研究的目的:
- 为了确定健康对照 (HC),aMCI和AD患者之间的结构性大脑差异.
- 在这些群体中探索大脑结构和认知功能之间的关系.
- 为了评估AD诊断的潜在神经成像生物标志物.
主要方法:
- 招募了46名参与者进入AD,aMCI和HC组.
- 使用结构磁共振成像 (sMRI) 来获取数据.
- 应用基于声素的形态测量 (VBM) 和基于表面的形态测量 (SBM) 用于区域分析和与认知得分 (MMSE,MoCA) 相关的发现.
主要成果:
- 在AD/aMCI患者中,与HC患者相比,观察到左前体积 (VBM) 和双侧下体厚度 (SBM) 的减少.
- 在左前皮质体积和MMSE/MoCA得分之间发现了显著的相关性.
- 在下体厚度和MMSE/MoCA得分之间发现了显著的相关性.
结论:
- 在前骨和下骨区域的结构性大脑变化与阿尔茨海默病和aMCI的认知衰退有关.
- 这些已识别的sMRI特征显示了作为AD的预测性诊断生物标志物的潜力.
更多相关视频
08:43Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
7.8K
11:01Examining the Characteristics of Episodic Memory using Event-related Potentials in Patients with Alzheimer's Disease
Published on: August 30, 2011
13.6K
相关概念视频
01:26Alzheimer's Disease: Overview
444
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
444
01:22Alzheimer's Disease: Treatment
162
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
162
01:30Dementia
94
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
94
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
95
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
95
01:19Role of Hippocampus in Memory
157
The hippocampus, a critical brain structure, plays an essential role in memory processing, particularly in the formation and retrieval of memory. This small, seahorse-shaped region is located within the medial temporal lobe, with one hippocampus in each brain hemisphere. Experimental studies involving lesions in the hippocampi of rats have demonstrated significant impairments in tasks such as object recognition and maze navigation, indicating the hippocampus involvement in both recognition and...
157